Skip to content

Rapport Therapeutics

US · RAPP #2970 by market cap Listed 2024
23.16 -0.43 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
  • Total institutional ownership fell 18.2 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
89.74% -18.16pp
Institutions
187 -2
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund43.74%
VC/PE Fund29.90%
Hedge Fund11.52%
Individual/Insider3.39%
Public Company3.36%
Insurance Company0.44%
Private Company0.36%
Endowment Fund0.21%
Government Pension Fund0.18%
Other6.90%

Top holders as of 2026-10-30

Third Rock Ventures, LLC 14.64% · 8.68M sh
FMR 12.14% · 7.20M sh
Arch Venture Partners, L.P. 6.29% · 3.73M sh
Capital Research 5.41% · 3.21M sh
BlackRock 4.86% · 2.88M sh
Cormorant Asset Management, LP 4.48% · 2.66M sh
Sofinnova Investments, Inc. 3.21% · 1.90M sh
Johnson & Johnson Innovation - JJDC, Inc. 3.01% · 1.78M sh
The Goldman Sachs Group, Inc. 2.81% · 1.66M sh
Polar Capital Holdings Plc 2.71% · 1.61M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 28 sells

NameRoleStake
Third Rock Ventures, LLC -- 14.64%
Steven Paul Founder & Independent Chairman 0.94%
Abraham Ceesay CEO, President, Treasurer & Director 0.93%
David Bredt Founder & Chief Scientific Officer 0.66%
Swamy Yeleswaram Chief Development Officer 0.33%
Cheryl Gault Chief Operating Officer 0.22%
Bradley Galer Former Chief Medical Officer 0.19%
Reid Huber Director 0.03%
Troy Ignelzi Chief Financial Officer 0.03%
Wendy Young Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-29 Third Rock Ventures, LLC -- Private Acquisition +1,428,571 $21.00
2026-10-22 Raymond Sanchez Independent Director Open Market Acquisition +3,600 $27.35
2026-10-21 John Michael Maraganore Independent Director Open Market Acquisition +9,411 $26.38–26.92
2026-10-21 Steven Paul Founder & Independent Chairman Open Market Acquisition +35,714 $27.28
2026-10-21 Paul Silva Independent Director Open Market Acquisition +3,680 $27.08
2026-10-21 Wendy Young Independent Director Open Market Acquisition +3,789 $26.39
2026-10-20 Troy Ignelzi Chief Financial Officer Open Market Acquisition +5,500 $26.10
2026-10-20 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -2,210 $29.16
2026-10-06 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -4,522 $30.66–32.03
2026-10-05 Abraham Ceesay CEO, President, Treasurer & Director Intent to Sell (Form 144) -39,470 $31.15
2026-09-29 Cheryl Gault Chief Operating Officer Automatic Disposition -10,000 $33.04–33.76
2026-09-22 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -2,210 $39.05–41.05
2026-09-07 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -8,210 $45.56–46.01
2026-08-24 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -18,921 $49.57
2026-08-24 Swamy Yeleswaram Chief Development Officer Automatic Disposition -50,160 $50.00–51.06
2026-08-18 Swamy Yeleswaram Chief Development Officer Automatic Disposition -404 $49.90
2026-08-10 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -51,499 $45.97–48.62
2026-07-26 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -2,210 $42.11–42.74
2026-07-13 Abraham Ceesay CEO, President, Treasurer & Director Automatic Disposition -8,210 $39.72–40.57
2026-06-29 Cheryl Gault Chief Operating Officer Automatic Disposition -10,000 $40.09–43.15

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rapport Therapeutics discussion 0 comments

Add a comment